Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1996 Feb;74(2):152–156. doi: 10.1136/adc.74.2.152

Lymphoblastoid interferon alfa treatment in chronic hepatitis C.

R Iorio 1, P Pensati 1, S Porzio 1, I Fariello 1, S Guida 1, A Vegnente 1
PMCID: PMC1511509  PMID: 8660080

Abstract

Interferon is becoming the standard treatment in adults for chronic hepatitis C. Twenty one children with histologically proved chronic hepatitis C (10 boys, range 2.5-13 years), who were otherwise healthy, were enrolled in a randomised controlled study to test their response to interferon alfa. Eleven children were treated with lymphoblastoid interferon alfa (3 million units/m2) for 12 months; 10 children received no treatment. All had raised transaminases and positive antihepatitis C virus (HCV) antibodies and HCV-RNA. Alanine aminotransferase (ALT) serum levels became normal in five (45%) treated patients after a mean of three weeks (range 1-6 weeks) and no relapse had occurred by the end of follow up (30th month). Only one (10%) untreated patient had normal ALT serum levels from the 11th until the 30th month. Disappearance of serum HCV-RNA, persisting throughout the follow up period, was observed in the six children (five treated) whose ALT became normal. Biopsy specimens in treated patients showed a significant improvement in Knodell's score (median (SD) basal 9.0 (2.2); final 2.0 (0.4)). Interferon treatment was well tolerated in all. This study confirms the efficacy of interferon in children with chronic hepatitis C, not only by restoring normal ALT serum levels, but also viral clearance and histological amelioration of liver inflammation. Contrary to reports in adults no biochemical and virological relapses occurred in responder children.

Full text

PDF
152

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alter M. J., Margolis H. S., Krawczynski K., Judson F. N., Mares A., Alexander W. J., Hu P. Y., Miller J. K., Gerber M. A., Sampliner R. E. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992 Dec 31;327(27):1899–1905. doi: 10.1056/NEJM199212313272702. [DOI] [PubMed] [Google Scholar]
  2. Alter M. J., Sampliner R. E. Hepatitis C: and miles to go before we sleep. N Engl J Med. 1989 Nov 30;321(22):1538–1540. doi: 10.1056/NEJM198911303212208. [DOI] [PubMed] [Google Scholar]
  3. Bortolotti F., Vajro P., Cadrobbi P., Lepore L., Zancan L., Barbera C., Crivellaro C., Fontanella A., Alberti A., D'Addezio M. Cryptogenic chronic liver disease and hepatitis C virus infection in children. J Hepatol. 1992 May;15(1-2):73–76. doi: 10.1016/0168-8278(92)90014-g. [DOI] [PubMed] [Google Scholar]
  4. Colombo M., Kuo G., Choo Q. L., Donato M. F., Del Ninno E., Tommasini M. A., Dioguardi N., Houghton M. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet. 1989 Oct 28;2(8670):1006–1008. doi: 10.1016/s0140-6736(89)91016-7. [DOI] [PubMed] [Google Scholar]
  5. De Groote J., Desmet V. J., Gedigk P., Korb G., Popper H., Poulsen H., Scheuer P. J., Schmid M., Thaler H., Uehlinger E. A classification of chronic hepatitis. Lancet. 1968 Sep 14;2(7568):626–628. doi: 10.1016/s0140-6736(68)90710-1. [DOI] [PubMed] [Google Scholar]
  6. Iorio R., Guida S., Porzio S., Fariello I., Vegnente A. Chronic non-A, non-B hepatitis: role of hepatitis C virus. Arch Dis Child. 1993 Feb;68(2):219–222. doi: 10.1136/adc.68.2.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kasahara A., Hayashi N., Hiramatsu N., Oshita M., Hagiwara H., Katayama K., Kato M., Masuzawa M., Yoshihara H., Kishida Y. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology. 1995 Feb;21(2):291–297. [PubMed] [Google Scholar]
  8. Kiyosawa K., Sodeyama T., Tanaka E., Gibo Y., Yoshizawa K., Nakano Y., Furuta S., Akahane Y., Nishioka K., Purcell R. H. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990 Oct;12(4 Pt 1):671–675. doi: 10.1002/hep.1840120409. [DOI] [PubMed] [Google Scholar]
  9. Knodell R. G., Ishak K. G., Black W. C., Chen T. S., Craig R., Kaplowitz N., Kiernan T. W., Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981 Sep-Oct;1(5):431–435. doi: 10.1002/hep.1840010511. [DOI] [PubMed] [Google Scholar]
  10. Kumar U., Monjardino J., Thomas H. C. Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology. 1994 Apr;106(4):1072–1075. doi: 10.1016/0016-5085(94)90770-6. [DOI] [PubMed] [Google Scholar]
  11. Lau J. Y., Davis G. L. Managing chronic hepatitis C virus infection. BMJ. 1993 Feb 20;306(6876):469–470. doi: 10.1136/bmj.306.6876.469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lau J. Y., Mizokami M., Ohno T., Diamond D. A., Kniffen J., Davis G. L. Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet. 1993 Nov 13;342(8881):1208–1209. doi: 10.1016/0140-6736(93)92187-x. [DOI] [PubMed] [Google Scholar]
  13. Lisker-Melman M., Di Bisceglie A. M., Usala S. J., Weintraub B., Murray L. M., Hoofnagle J. H. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology. 1992 Jun;102(6):2155–2160. doi: 10.1016/0016-5085(92)90348-3. [DOI] [PubMed] [Google Scholar]
  14. Lunel F., Musset L., Cacoub P., Frangeul L., Cresta P., Perrin M., Grippon P., Hoang C., Valla D., Piette J. C. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology. 1994 May;106(5):1291–1300. doi: 10.1016/0016-5085(94)90022-1. [DOI] [PubMed] [Google Scholar]
  15. Misiani R., Bellavita P., Fenili D., Vicari O., Marchesi D., Sironi P. L., Zilio P., Vernocchi A., Massazza M., Vendramin G. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med. 1994 Mar 17;330(11):751–756. doi: 10.1056/NEJM199403173301104. [DOI] [PubMed] [Google Scholar]
  16. Okamoto H., Okada S., Sugiyama Y., Tanaka T., Sugai Y., Akahane Y., Machida A., Mishiro S., Yoshizawa H., Miyakawa Y. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5'-noncoding region. Jpn J Exp Med. 1990 Aug;60(4):215–222. [PubMed] [Google Scholar]
  17. Okamoto H., Sugiyama Y., Okada S., Kurai K., Akahane Y., Sugai Y., Tanaka T., Sato K., Tsuda F., Miyakawa Y. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol. 1992 Mar;73(Pt 3):673–679. doi: 10.1099/0022-1317-73-3-673. [DOI] [PubMed] [Google Scholar]
  18. Pagliaro L., Craxí A., Cammaá C., Tiné F., Di Marco V., Lo Iacono O., Almasio P. Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology. 1994 Apr;19(4):820–828. [PubMed] [Google Scholar]
  19. Ruiz-Moreno M., Rua M. J., Castillo I., García-Novo M. D., Santos M., Navas S., Carreño V. Treatment of children with chronic hepatitis C with recombinant interferon-alpha: a pilot study. Hepatology. 1992 Oct;16(4):882–885. doi: 10.1002/hep.1840160405. [DOI] [PubMed] [Google Scholar]
  20. Seeff L. B., Buskell-Bales Z., Wright E. C., Durako S. J., Alter H. J., Iber F. L., Hollinger F. B., Gitnick G., Knodell R. G., Perrillo R. P. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med. 1992 Dec 31;327(27):1906–1911. doi: 10.1056/NEJM199212313272703. [DOI] [PubMed] [Google Scholar]
  21. Terrault N., Wright T. Interferon and hepatitis C virus infection. N Engl J Med. 1995 Jun 1;332(22):1509–1511. doi: 10.1056/NEJM199506013322211. [DOI] [PubMed] [Google Scholar]
  22. Tomimatsu M., Ishiguro N., Taniai M., Okuda H., Saito A., Obata H., Yamamoto M., Takasaki K., Nakano M. Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan. Cancer. 1993 Aug 1;72(3):683–688. doi: 10.1002/1097-0142(19930801)72:3<683::aid-cncr2820720310>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  23. Tran A., Quaranta J. F., Benzaken S., Thiers V., Chau H. T., Hastier P., Regnier D., Dreyfus G., Pradier C., Sadoul J. L. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology. 1993 Aug;18(2):253–257. [PubMed] [Google Scholar]
  24. Tsubota A., Chayama K., Ikeda K., Yasuji A., Koida I., Saitoh S., Hashimoto M., Iwasaki S., Kobayashi M., Hiromitsu K. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology. 1994 May;19(5):1088–1094. [PubMed] [Google Scholar]
  25. Tsubota A., Chayama K., Ikeda K., Yasuji A., Koida I., Saitoh S., Hashimoto M., Iwasaki S., Kobayashi M., Hiromitsu K. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology. 1994 May;19(5):1088–1094. [PubMed] [Google Scholar]
  26. Vergani D., Mieli-Vergani G. Type II autoimmune hepatitis. What is the role of the hepatitis C virus? Gastroenterology. 1993 Jun;104(6):1870–1873. doi: 10.1016/0016-5085(93)90673-z. [DOI] [PubMed] [Google Scholar]
  27. Wright T. L., Donegan E., Hsu H. H., Ferrell L., Lake J. R., Kim M., Combs C., Fennessy S., Roberts J. P., Ascher N. L. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology. 1992 Jul;103(1):317–322. doi: 10.1016/0016-5085(92)91129-r. [DOI] [PubMed] [Google Scholar]
  28. Yee H. F., Jr, Wright T. L. Serum ALT: tarnished gold standard for interferon response in hepatitis C virus infection. Hepatology. 1994 Jun;19(6):1531–1533. doi: 10.1002/hep.1840190632. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES